Chronic Plaque Psoriasis Market Report Examines Leading Companies And Growth Opportunities

An Overview of the Chronic Plaque Psoriasis Market Outlook
The chronic plaque psoriasis market is set for notable expansion in the coming years, driven by advancements in treatment options and growing patient demand. As innovative therapies continue to emerge, the market is poised for steady growth fueled by cutting-edge biologics and personalized care strategies. Let's explore the market's size projections, key players, evolving trends, and segment breakdowns shaping this healthcare sector.

Projected Market Size and Growth Forecast for Chronic Plaque Psoriasis
By 2030, the global chronic plaque psoriasis market is anticipated to reach a valuation of $30.99 billion, expanding at a compound annual growth rate (CAGR) of 6.8%. This momentum is supported by the rise of next-generation biologics, increasing adoption of oral immunomodulators, and the broader application of precision dermatology techniques. Greater emphasis on patient-centric treatment approaches and heightened investment in autoimmune disease research are also significant contributors to the market expansion. Emerging patterns in this period include a growing preference for biologic therapies, targeted small molecule drugs, enhanced oral treatment availability, personalized dermatology care, and a stronger focus on sustained disease management.

The chronic plaque psoriasis market size has grown strongly in recent years. It will grow from $22.26 billion in 2025 to $23.83 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to improved diagnosis of autoimmune skin disorders, wider availability of topical therapies, increased awareness of psoriasis management, expansion of dermatology clinics, improved access to specialty drugs.

Download a free sample of the chronic plaque psoriasis market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Corporations Dominating the Chronic Plaque Psoriasis Sector
The chronic plaque psoriasis market features several prominent companies, including Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy's Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, and Biogen Inc.
A significant recent development occurred in October 2024 when Organon, a US-based healthcare firm, acquired Dermavant Sciences Ltd. This move bolsters Organon's dermatology offerings by adding VTAMA (tapinarof) Cream, 1%, a novel topical therapy. VTAMA Cream, approved by the FDA, is a unique non-biologic, non-steroidal treatment designed for adult patients with mild to severe plaque psoriasis. Dermavant Sciences is known for pioneering innovative immunodermatology therapies, enhancing Organon's portfolio in this therapeutic field.

Key Drivers Behind Growth in the Chronic Plaque Psoriasis Market
One of the main drivers propelling this market is the rapid advancement and development of innovative biologic treatments targeting specific immune system pathways. These therapies offer more effective and tailored options for managing chronic plaque psoriasis, which significantly impacts patient quality of life.
Additionally, the expanding focus on personalized medicine within dermatology fosters better patient outcomes by customizing treatment plans according to individual genetic and clinical profiles. This patient-centric approach is encouraging wider adoption of precision therapies, further stimulating market demand.

View the full chronic plaque psoriasis market report:
https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Important Trends Shaping the Future of Chronic Plaque Psoriasis Treatments
Pharmaceutical companies are increasingly focused on pioneering therapies that inhibit IL-17A and IL-17F, two pro-inflammatory cytokines critical in the development of psoriasis. These targeted biologics represent a transformative approach to managing inflammation more precisely.
For example, in October 2023, UCB S.A., based in Belgium, received FDA approval for BIMZELX (bimekizumab-bkzx). This medication is indicated for adults with moderate to severe plaque psoriasis who require systemic therapy or phototherapy. BIMZELX is the first treatment to simultaneously block IL-17A and IL-17F, backed by robust safety and efficacy data from Phase 3 trials BE READY, BE VIVID, and BE SURE involving 1,480 patients.

Breakdown of Chronic Plaque Psoriasis Market Segmentation
This report segments the chronic plaque psoriasis market by drug class, route of administration, and distribution channels.
- Drug Class includes Biologics and Small Molecule Drugs.
- Routes of Administration cover Injectable, Oral, and Topical medications.
- Distribution Channels consist of Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Further subcategories provide detailed classification:
- Within Biologics, there are Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (such as IL-12, IL-23, IL-17, IL-22), and T-Cell Inhibitors.
- Small Molecule Drugs encompass Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, and Retinoids.

This structured segmentation highlights the diverse therapeutic options and delivery methods available, reflecting the dynamic nature of the chronic plaque psoriasis treatment landscape.

New analytical features added to our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.